• CEO Dr Philippe Wolgen to take temporary leave for medical treatment
• Executive team to assume day-to-day responsibilities, with COO Lachlan Hay appointed Acting CEO
• Board supports Dr Wolgen's decision to focus on his health and recovery

Clinuvel Pharmaceuticals Ltd has announced that its Chief Executive Officer, Dr Philippe Wolgen, will take temporary leave from his full duties to seek treatment for an acute medical condition. The Company's existing executive team will assume Dr Wolgen's day-to-day responsibilities for up to three months, with Chief Operations Officer Lachlan Hay appointed by the Board to the role of Acting CEO under Dr Wolgen's guidance. Dr Wolgen stated that the temporary reduction of his operational involvement will result in the fastest path to full health, and he has complete faith in the executive team to continue delivering without disruption to the business. The Board supports Dr Wolgen's decision to focus on his health and recovery, and wishes him a speedy recovery. The Company will continue to work closely with the executive team as they execute on Clinuvel's objectives.